Simple blood and tissue tests could revolutionize lung cancer care
NCT ID NCT05665504
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study is testing whether certain biomarkers in blood and lung tissue can help doctors tell if a lung nodule is cancer, predict the risk of cancer coming back after surgery, and monitor for late recurrence. Researchers will follow 250 people with suspicious lung nodules or recent lung cancer surgery. The goal is to improve diagnosis and personalize follow-up care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DetermaRX (tissue biomarker test), LCDT-1, NodifyXL2, CIZ1b (blood biomarker tests)
What this could lead to
If successful, these biomarker tests could help doctors more accurately diagnose lung nodules, decide who needs chemotherapy after surgery, and catch cancer returning earlier.
What could go wrong
This is an observational study, not a treatment trial. The tests may not prove accurate enough to change standard care, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.